Sentences with phrase «for allogeneic donors»

Not exact matches

The subindication for which now data were available for the first time was allogeneic SCT with related donor in comparison with allogeneic SCT with unrelated donor.

HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.

Of these 34 patients, 13 (38 %) have remained in remission for five years, and an additional two patients whose disease did not progress after BV went on to achieve remission after receiving allogeneic stem cell transplant (in which healthy stem cells are taken from a donor and administered to the patient).

Mehta J, Gordon LI, Tallman MS, et al., Does younger donor age affect the outcome of reduced - intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Allogeneic Sibling Donor Peripheral Blood Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe Phase of the Disease

We are planning to develop a product that would be an allogeneic, or donor - derived product, that could be used for similar indications in children and babies who don't have their own cell store.

In the future, outpatient blood and bone marrow stem cell transplantation will be offered to a broader group of patients with other blood disorders and for allogeneic transplants (transplant from non-twin donor stem cells).

Low - dose donor CD8 + cells in the CD4 - depleted graft prevent allogeneic marrow graft rejection and severe graft - versus - host disease for chronic myeloid leukemia patients in first chronic phase.

(A and B) Flow cytometry analysis of intracellular IFN - γ and IL - 17A on donor - derived CD4 + T cells from spleen on indicated days for syngeneic and allogeneic mice.

Allogeneic cell therapies from primary cells for immunotherapy applications are especially challenging because of the vigor with which tissue donors must be screened and qualified to prevent transmission of infectious disease and ensure maintenance of an active donor pool.

Thus, one can transplant fully allogeneic hematopoietic stem cells and co-transplant, for example, hearts from the hematopoietic stem cell donor to induce lifelong donor - specific acceptance of the transplant, without deleterious immunosuppression [4].

It offers to the commercialization of unrelated donor - patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.